Literature DB >> 11041568

Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.

J H Lee1, K H Lee, S J Choi, Y J Min, J G Kim, S Kim, J S Lee, S H Kim, C J Park, H S Chi, W K Kim.   

Abstract

There are few reports about the occurrence of hepatic VOD after BMT for severe aplastic anemia (SAA). We prospectively studied 17 patients with SAA after allogeneic BMT for the occurrence and severity of VOD. Plasma levels of protein C, protein S, antithrombin III, vWF, t-PA and PAI-1 were determined before preparative chemotherapy, on the day of marrow infusion, and on days 7, 14 and 21. VOD occurred in seven patients (41.2%) at a median of day 1 (range, day -2 to 15). Five had mild, and two moderate VOD. Platelet transfusion requirements were higher in the patients with VOD. The plasma levels of natural anticoagulants such as protein C, free protein S and antithrombin III decreased significantly on day 0 from the baseline levels. Plasma levels of t-PA, PAI-1 and vWF increased significantly in the early post-transplant period compared to the baseline levels. The mean plasma levels of t-PA on day 7 (P = 0.016) and PAI-1 on days 0 and 7 (P = 0.016, 0.032) were higher in the patients with VOD. In summary, we observed hypercoagulability and a high incidence of VOD after allogeneic BMT for SAA. Levels of t-PA and PAI-1 were significantly higher in the patients with VOD after BMT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11041568     DOI: 10.1038/sj.bmt.1702583

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Preclinical validation and treatment of volumetric modulated arc therapy based total bone marrow irradiation in Halcyon™ ring gantry linear accelerator.

Authors:  Tanweer Shahid; Sourav Mandal; Subhra Snigdha Biswal; Arundhati De; Mukti Mukherjee; Sandipan Roy Chowdhury; Anupam Chakrapani; Kirubha George; Jibak Bhattacharya; Prosenjit Soren; Tanmoy Ghosh; Biplab Sarkar; Luca Cozzi
Journal:  Radiat Oncol       Date:  2022-08-19       Impact factor: 4.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.